Coherus Q1 revenue $77.1M, net income $102.9M; UDENYCA +63% YoY; LOQTORZI launch underway

Coherus Oncology, Inc.

2024-Q1 EPS reported $0.83 revenue$77,063,000

Net revenue $77.1M in Q1 2024 vs $32.4M in Q1 2023; GAAP net income $102.9M ($0.83 diluted EPS) vs net loss of $75.7M.
UDENYCA net sales $42.7M, up 18% QoQ and 63% YoY; LOQTORZI launch sales $2.0M; CIMERLI divested for $187.8M cash.
Non-GAAP net loss $35.8M (-$0.32 per share), improved from non-GAAP net loss $59.5M in Q1 2023.
New debt and royalty financing replaces $75M term loan; debt maturity extended to May 2029.
Entered partnership with CRI and ENB Therapeutics to study toripalimab in ovarian cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Coherus Oncology, Inc. reported the quarter ended March 31, 2024 results: revenue $77.1 million, net income $102.9 million, EPS $0.83 per share on a diluted basis.

Period: the quarter ended March 31, 2024
Revenue: $77.1 million
Net income: $102.9 million
EPS: $0.83 per share on a diluted basis
Result: reported results

Exact text from the filing

reference in such a filing. --- EX-99.1 (EX-99.1) --- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update – Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.